Slide 1: 3Q25 Earnings Presentation
3Q25 Earnings Presentation October 29, 2025
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 3Q25 Main Highlights
3Q25 Main Highlights 8.3% INCREASE IN PHARMACEUTICAL RETAIL SELL-OUT¹ +1.9 PERCENTAGE POINT VS. MARKET GROWTH IN THE CATEGORIES IN WHICH THE COMPANY OPERATES +2.8 PERCENTAGE POINTS VS. GROWTH IN 2Q25 EBITDA MARGIN FROM CONTINUING OPERATIONS OF 34% RECORD OPERATING CASH FLOW OF R$853.6 MILLION REDUCT
Slide 4: 3Q25 Main Highlights
3Q25 Main Highlights APPROVAL OF INTEREST ON EQUITY IN THE AMOUNT OF R$185.1 MILLION (R$0.29/share) UPDATE ON THE ADVISORY COMMITTEES OF THE BOARD OF DIRECTORS STATUTORY AUDIT COMMITTEE: Carla Trematore, Eliana Chimenti and Hugo Leal PEOPLE COMMITTEE (COMPENSATION): Álvaro Stainfeld, Ana Lúcia Calta
Slide 5: 3Q25 Results (R$ million)
3Q25 Results (R$ million) NET REVENUE R$ 2,227.2 +16.3%1 GROSS MARGIN 61.2%2 +140bps3 MARKETING EXPENSES R$ 366.6 +5.6%1 SELLING EXPENSES R$ 236.3 -5.2%1 GENERAL AND ADMINISTRATIVE EXPENSES R$ 84.6 -13.9%1 EBITDA MARGIN FROM CONTINUING OPERATIONS 34.0%2 +470bps3 NET EARNINGS FROM CONTINUING OPERATIO
Slide 6: 3Q25 Cash Flow (R$ million)
3Q25 Cash Flow (R$ million) 854 689 (110) (55) (4) (24) 1,864 1,204 7,269 (9,133) Gross Cash at the Cash Flow From PP&E Intangibles 3Q25 Free Cash Financing Cash IoC Gross Cash at the Gross Debt at the Net Debt at the end of 2Q25 Operations Flow Flow end of 3Q25 end of 3Q25 end of 3Q25 Note: Cash Fl
Slide 7: efd
efd harma